Advocacy achievements of the bridging the gaps global partners
Accessed: 17.11.2019
It's time to deliver differently.
Accessed: 13.11.2019
Inter-Agency Task Team on HIV and Young People
Guidance Brief
Accessed: 09.11.2019
Lancet Glob Health 2019Published OnlineOctober 22, 2019 https://doi.org/10.1016/S2214-109X(19)30425-5
The GHS Index is intended to be a key resource in the face of increasing risks of high-consequence and globally catastrophic biological events and in light of major gaps in international financing for preparedness. These risks are magnified by a rapidly changing and interconnected world; increasing ...political instability; urbanization; climate change; and rapid technology advances that make it easier, cheaper, and faster to create and engineer pathogens.
Key findings from the study of 195 countries:
• Out of a possible 100 points, the average GHS Index score across 195 countries was 40.2.
• The majority of high- and middle-income countries do not score above 50.
• Action is urgently needed to improve countries’ readiness for high-consequence infectious disease outbreaks.
more
From passive beneficiaries to active agents of change
Final Report
Submitted to: Unicef, New Delhi
ORG Centre for Social Research (A Division of AC Nielsen ORG- MARG Private Limited)
Accessed: 30.10.2019
PLOS ONE | https://doi.org/10.1371/journal.pone.0217693 June 7, 2019
Enquête Démographique et de Santé 2017-2018 Rapport de synthèse, Bénin
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
Summary Report
Accessed: 19.10.2019
Toolkit
HIV Treatment and Care